全国服务咨询热线：
18438616290
18438616290
产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 1201902-80-8 |
|---|---|---|---|
| 分子式 | C20H23BCl2N2O9 | 纯度 | ＞98% |
| 分子量 | 517.12 | 货号 | abs810676 |
| 规格 | 10mg | 供货周期 | 现货 |
| 主要用途 | is a proteasome inhibitor, | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
Ixazomib Citrate 1201902-80-8
| 产品描述 | |
| 描述 | MLN-9708 is a proteasome inhibitor, which inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome. |
| 纯度 | >98% |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 别名 | 艾沙佐米柠檬酸盐;Ixazomib；MLN-9708；MLN9708；MLN 9708 |
| 外观 | White to Off-White Solid |
| 可溶性/溶解性 | DMSO ：100 mg/mL (193.37 mM) |
| 生物活性 | |
| In vitro(体外研究) | MLN9708 is a selective, orally bioavailable, second-generation proteasome inhibitor. MLN9708 has a shorter proteasome dissociation half-life and improved pharmacokinetics, pharmacodynamics, and antitumor activity compared with bortezomib, which we believe plays an important role in its improved tissue distribution. MLN9708 has a larger blood volume distribution at steady state, and analysis of 20S proteasome inhibition and markers of the unfolded protein response confirms that MLN9708 has greater pharmacodynamic effects in tissues than bortezomib. MLN9708 is a second-generation small-molecule proteasome inhibitor being developed for the treatment of a broad range of human malignancies. Upon exposure to aqueous solutions or plasma, MLN9708 rapidly hydrolyzes to its biologically active form MLN2238. MLN2238 is the biologically active form of MLN9708. |
| In vivo(体内研究) | MLN9708 shows superior antitumor activity in both solid tumor and hematologic preclinical xenograft models when administered via multiple dosing routes and regimens. Recent preclinical pharmacology studies shows that MLN9708 has a shorter proteasome dissociation half-life than bortezomib, as well as improved pharmacokinetics, pharmacodynamics, and antitumor activity in xenograft models MLN9708 has shown antitumor efficacy in a wide range of tumor xenografts |
| 研究领域 | |
| 研究领域 | Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询
地址：上海市浦东新区新浩路58号申江科创园18栋
邮箱：lanwu@univ-bio.com
传真：